Article Text

PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines
  1. Francesca Gattino, DVM1,
  2. Lorella Maniscalco, DVM, PhD1,
  3. Selina Iussich, DVM1,
  4. Ilaria Biasato, DVM1,
  5. Marina Martano, DVM, PhD1,
  6. Emanuela Morello, DVM, PhD1,
  7. Cecilia Gola, DVM1,
  8. Yolanda Millán Ruiz, DVM, PhD2,
  9. Nobuo Saeki, DVM, PhD3,
  10. Paolo Buracco, DVM, PhD, Dipl. ECVS1,
  11. Juana Martín de las Mulas, DVM, PhD2 and
  12. Raffaella De Maria, DVM, PHd1
  1. 1Department of Veterinary Sciences, University of Turin, Turin, Italy
  2. 2Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain
  3. 3Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan
  1. E-mail for correspondenceDepartment of Veterinary SciencesUniversity of TurinTurinItaly; francesca.gattino{at}


Canine mammary tumours (CMTs) are one of the most common malignancies in bitches. Platelet-derived growth factor receptor (PDGFR) α and β, vascular endothelial growth factor receptor-2 (VEGFR-2) and CD117 are tyrosine kinase receptors involved in several tumours and represent suitable targets for specific therapy with toceranib phosphate. The purpose of this study was to evaluate the expression of these receptors in the pathogenesis and progression of CMTs. PDGFRα, PDGFRβ, VEGFR-2 and CD117 were expressed in 46/83 (55.4 per cent), 33/83 (39.8 per cent), 46/83 (55.4 per cent) and 32/83 (38.5 per cent) of CMTs, respectively. Immunohistochemical results showed a statistically significant loss of PDGFRα and PDGFRβ expression in simple carcinomas compared with complex/mixed carcinomas. Protein expression by western blot revealed specific bands corresponding to PDGFRα and VEGFR-2 in 3/7 and in 1/7 cell lines. Moreover, in vitro treatment showed that toceranib phosphate weakly reduced cell proliferation in one canine mammary cell line. Before considering TKR inhibitors for possible therapeutic approaches, actually further studies are necessary to evaluate the effect of these drugs on CMTs in vivo.

  • tyrosine kinases receptors
  • toracenib phosphate
  • mammary tumors
  • immunohistochemistry
  • dog
  • cell lines
  • platelet-derived growth factor receptor
  • vascular endothelial growth factor

Statistics from


  • Competing interests None declared.

  • Ethics approval Retrospective collection and analysis on CMTs samples was approved by the Ethical Review Committee of the Department of Veterinary Science.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.